PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
held its 2017 Annual Meeting of Stockholders (the 2017 Annual
Meeting). The results of the stockholder voting at the 2017
Annual Meeting are set forth below:
of the Company to hold office until the next annual meeting of
shareholders and until their successors shall have been duly
elected and qualified.
|
Director Name
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
||||||||||||
|
Zami Aberman
|
22,799,652
|
1,987,332
|
188,268
|
19,435,840
|
||||||||||||
|
Israel Ben-Yoram
|
23,607,522
|
575,814
|
791,916
|
19,435,840
|
||||||||||||
|
Isaac Braun
|
23,615,503
|
571,645
|
788,104
|
19,435,840
|
||||||||||||
|
Mark Germain
|
23,625,763
|
563,739
|
785,750
|
19,435,840
|
||||||||||||
|
Moria Kwiat
|
22,899,597
|
1,855,606
|
220,049
|
19,435,840
|
||||||||||||
|
Hava Meretzki
|
22,681,130
|
2,059,153
|
234,969
|
19,435,840
|
||||||||||||
|
Nachum Rosman
|
24,159,423
|
574,496
|
241,333
|
19,435,840
|
||||||||||||
|
Doron Shorrer
|
22,702,336
|
2,033,407
|
239,509
|
19,435,840
|
||||||||||||
|
Yaky Yanay
|
22,848,791
|
1,994,757
|
131,704
|
19,435,840
|
Executive Officers
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
18,941,992
|
5,696,599
|
336,661
|
19,435,840
|
Kasierer, a member of Ernst Young Global, as independent
registered public accounting firm of the Company for the fiscal
year ending June 30, 2017.
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
41,664,170
|
1,106,491
|
1,640,431
|
–
|
About PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI)
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases. PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Recent Trading Information
PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) closed its last trading session up +0.02 at 1.40 with 157,186 shares trading hands.
